Navigation Links
Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
Date:2/7/2008

WALTHAM, Mass., Feb. 7 /PRNewswire/ -- Logical Therapeutics, Inc., a biotechnology company focused on the development of medicines that treat diseases associated with poorly controlled inflammation, announced today that its co-founder and CEO Mitchell P. Fink M.D. was presented with the Distinguished Investigator Award from the American College of Critical Care Medicine during the 37th Critical Care Congress of the Society of Critical Care Medicine held February 2-6 in Honolulu, Hawaii.

The prestigious recognition was awarded to Dr. Fink for his pioneering research related to the pathogenesis and treatment of sepsis, a serious medical condition characterized by widespread inflammation, due to infection.

Dr. Fink was the Founding Chairman of the Department of Critical Care Medicine at the University of Pittsburgh, the first such department at a medical school in the United States. Dr Fink also held other University appointments including Professor of Pharmacology, the Watson Professor of Surgery, and Associate Vice-chancellor for Translational Research. Dr. Fink's academic research program was continuously funded by the National Institutes of Health for more than 20 years.

The Society of Critical Care Medicine, which bestowed the honor to Dr. Fink, is the leading professional organization dedicated to ensuring excellence and consistency in the practice of critical care medicine. With more than 13,000 members worldwide, the Society is the only professional organization devoted exclusively to the advancement of multi-professional intensive care through excellence in patient care, professional education, public education, research and advocacy.

Dr. Fink is an author or co-author of more than 250 peer-reviewed scientific publications, has edited or co-edited 13 textbooks and is currently an Associate Editor for two highly regarded scientific journals: the Journal of Pharmacology and Experimental Therapeutics and the Journal of Leukocyte Biology.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are caused by or are associated with excessive inflammation, including various forms of arthritis, obesity and type 2 diabetes mellitus. For more information on Logical Therapeutics, visit the company's website at http://www.logicaltherapeutics.com or by email at info@logicaltherapeutics.com


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Montana State University lab gives early warnings about biological invaders
4. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
5. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
10. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
11. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Brain ... to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting ... in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed ...
(Date:2/23/2017)... ... 2017 , ... Today, researchers can fast-track sample collection and ... other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With the ... between insulin and other relevant biomarkers can be extensively studied through a non-invasive ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: PETX), ... commercialization of innovative biopharmaceutical products for companion animals, will host ... 8:30 a.m. ET to discuss financial results from the fourth ... Interested participants and investors may access the audio ... ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):